Eli Lilly, having reached a $1.146 trillion market cap largely due to weight-loss drugs Mounjaro and Zepbound, is now showing strong growth potential in oncology, immunology, and neuroscience sectors, with Q2 revenue from these areas up 121% year over year. The company raised its 2026 revenue guidance to $85-$87 billion and plans to file retatrutide, a promising weight-loss drug, for approval in early 2027. Despite risks from price cuts and revenue concentration in weight-loss drugs, analysts remain bullish, projecting a 22.65% upside to a $1,572.21 price target over the next 12 months. Continued growth in cancer and immunology drugs could push the stock even higher in the coming years.
Eli Lilly’s expanding focus beyond weight-loss drugs is mirrored in its strong market presence on Pluang, where LLY trades at USD 1,422.52 with a 3.61% gain as of Oct 31, 2026 00:51 WIB. The company’s market cap on Pluang stands at $1.22 trillion, reflecting investor interest despite a high sell order activity of 91%. Typical hold time for LLY on the platform is 94 days, indicating moderate-term investor engagement.
Eli Lilly reported strong third-quarter results with a 39% increase in revenue to $24.4 billion, fueled by successful drug franchises like Mounjaro and Zepbound. The company’s growth is becoming more diversified with new products such as Foundayo, Re...
Eli Lilly's stock surged 6% to a record $1.3 trillion valuation after reporting stronger-than-expected earnings driven by sales of weight-loss drugs Mounjaro and Zepbound. Both drugs exceeded sales expectations by over 5%, reinforcing Eli Lilly's dom...
Eli Lilly reported a 38.6% year-over-year revenue increase to $24.4 billion in Q3, driven by strong sales of its diabetes and obesity treatments Mounjaro and Zepbound, which generated $16.08 billion, up 59.1% from last year. Sales of Ebglyss, a treat...
Merck's stock rose 5% following its Q3 2026 earnings report, which beat analyst expectations with adjusted EPS of $2.49 and revenue of $18.09 billion. The company raised its 2026 adjusted EPS guidance to $2.77-$2.82, driven by strong sales of its can...
Eli Lilly reported a record quarter driven by strong sales of its weight-loss injection, Zepbound. The company raised its 2026 revenue outlook for the third time this year, now expecting between $91 billion and $92 billion. This reflects the growing ...
